Skip to main content
Top
Published in: International Journal of Clinical Oncology 6/2016

01-12-2016 | Letter to the Editor

Prevalence of data fraud

Author: Stephen L. George

Published in: International Journal of Clinical Oncology | Issue 6/2016

Login to get access

Excerpt

I thank Professor Wiwanitkit for his letter. The primary purpose of my paper [1], as the title suggests, was to review the literature on the prevalence of scientific misconduct and contributing factors leading to misconduct. Although the existing evidence on these topics is rather problematic as I noted in the paper “The evidence on prevalence is unreliable and fraught with definitional problems and with study design issues”, I believe a reasonable interpretation of the available data indeed suggests that “…cases of the most serious types of misconduct, fabrication and falsification (i.e., data fraud), are relatively rare…”. Of course, the definition of ‘rare’ is not clear and it can be argued that an overall prevalence of 2 %, as suggested by a meta-analysis of studies of self-reported admissions of fabrication or falsification [2], not only suffers from a potentially large under-reporting bias but, even taken at face value, indicates a situation that is in fact not rare for such a serious breach of scientific ethics. In any case, data fraud does occur regularly, rarely or not, and it is certainly true that the complex issues of prevention and detection of data fraud deserve serious attention. …
Literature
1.
go back to reference George SL (2016) Research misconduct and data fraud in clinical trials: prevalence and causal factors. Int J Clin Oncol 21(1):15–21CrossRefPubMed George SL (2016) Research misconduct and data fraud in clinical trials: prevalence and causal factors. Int J Clin Oncol 21(1):15–21CrossRefPubMed
2.
Metadata
Title
Prevalence of data fraud
Author
Stephen L. George
Publication date
01-12-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0991-z

Other articles of this Issue 6/2016

International Journal of Clinical Oncology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine